Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma
European Journal of Nuclear Medicine and Molecular Imaging · 2025
DOI: 10.1007/s00259-025-07075-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Maximilian J Mair und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University Munich, Munich, Germany. Hauptthemen laut MEDLINE: Meningioma, Receptors, Somatostatin, Serine Endopeptidases, Meningeal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.
Abstract (Originalsprache)
Purpose
High-grade meningiomas have high recurrence rates and limited prognosis. Radioligand therapies are approved in extracranial malignancies, but their value in brain tumours including meningiomas is unclear, as data on target expression is scarce.
Methods
CNS WHO grade 2 and 3 meningioma samples were immunohistochemically stained for somatostatin receptor 2a (SSTR2a), fibroblast activation protein (FAP), and human epidermal growth factor receptors 2/3 (HER2/HER3). Target expression was correlated with (epi-)genetic tumour subtyping by DNA methylation analysis, genetic alterations, and survival.
Results
Meningioma samples of 58 patients were included. SSTR2a expression (membranous/cytoplasmic) was observed in 43/55 (78.2%), and FAP expression in 15/58 (25.9%) evaluable samples, with HER2 and HER3 expression in one specimen each (1.7%). Membranous SSTR2a expression was strong in 18 (32.7%), intermediate in 12 (21.8%), and weak in 11 (20.0%) samples. While SSTR2a expression was more homogenous and mainly seen in regions with higher cellularity, FAP immunoreactivity was predominantly seen in tumour stroma and regions of lower cellularity. SSTR2a immunoreactivity was associated with TRAF7 wildtype status ( p = 0.034). FAP expression was more frequent in meningiomas of CNS WHO grade 3 (vs. CNS WHO 2; p < 0.001), and samples with NF2 mutations ( p = 0.032) or CDKN2A/B deletions ( p = 0.013) compared to wildtype. FAP and SSTR2a expression (present vs. absent) were not associated with overall survival ( p > 0.05).
Conclusion
SSTR2a and FAP are expressed in high-grade meningioma samples to a variable extent, and differences across meningioma subtypes underscore the need for biomarkers to improve patient selection. Spatial heterogeneity of target expression should be considered in radioligand therapy design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, LMU Hospital, Ludwig Maximilians University Munich, Munich, Germany.
- Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- MINUTEmedical GmbH, Vienna, Austria.
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Neurosurgery, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Nathalie L Albert
Förderung
- Klinikum der Universität München
Zitieren
APA
Mair, M. J., Hartenbach, S., Tomasich, E., Maas, S. L. N., Bosch, S. A., Widhalm, G., Eckert, F., Sahm, F., Hainfellner, J. A., Hartenbach, M., Berghoff, A. S., Preusser, M., & Albert, N. L. (2025). Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07075-8
Vancouver
Mair MJ, Hartenbach S, Tomasich E, Maas SLN, Bosch SA, Widhalm G, et al. Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07075-8
BibTeX
@article{Mair2025,
author = {Mair, Maximilian J and Hartenbach, Sabrina and Tomasich, Erwin and Maas, Sybren L N and Bosch, Sarah A and Widhalm, Georg and Eckert, Franziska and Sahm, Felix and Hainfellner, Johannes A and Hartenbach, Markus and Berghoff, Anna S and Preusser, Matthias and Albert, Nathalie L},
title = {Expression of SSTR2a, FAP, HER2 and HER3 as potential radionuclide therapy targets in higher-grade meningioma},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
doi = {10.1007/s00259-025-07075-8}
}
EUVIMED